Recent Updates
Recently added Catalysts
REPL Positive Sentiment

Replimune Announces Pricing of $150 Million Underwritten Offering

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Replimune Group, Inc. has announced the pricing of an underwritten offering of 9,701,490 shares of its common stock, raising $150 million. This move is expected to enhance the company's financial resources, enabling further development of its innovative oncolytic immunotherapies. The offering reflects investor confidence in Replimune's growth potential.

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful pricing of a significant underwritten offering
  • Strengthens Replimune's financial position
  • Potential for further investment in oncolytic immunotherapies

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+581%
120-day peak, hindsight
Typical move
29.4%
average across 5 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
RP3
Phase 1 · Advanced Solid Tumor

Full Press Release Details

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL) (“Replimune”), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at an

Frequently Asked Questions

What is the amount raised in Replimune's offering?

Replimune raised $150 million through its underwritten offering.

How many shares were offered by Replimune?

Replimune offered 9,701,490 shares of its common stock.

What is the purpose of the stock offering?

The offering aims to strengthen Replimune's financial position for further development.

ShareAdd on Google
Tags: REPL Viatris Investor Conferences Healthcare Replimune oncolytic immunotherapies biotechnology stock offering
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$269M liquidity · $23M/mo burn
~10 mo
Medium dilution risk
Lead asset
RP3Phase 1
Advanced Solid Tumor →

Catalyst track record

+581%
best trade around REPL's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for REPL.

See every catalyst's timing & PoA →